Advertisement

The AAPS Journal

, Volume 15, Issue 3, pp 864–874 | Cite as

Epigenetic Modifications of Nrf2 by 3,3′-diindolylmethane In Vitro in TRAMP C1 Cell Line and In Vivo TRAMP Prostate Tumors

  • Tien-Yuan Wu
  • Tin Oo Khor
  • Zheng-Yuan Su
  • Constance Lay-Lay Saw
  • Limin Shu
  • Ka-Lung Cheung
  • Ying Huang
  • Siwang Yu
  • Ah-Ng Tony KongEmail author
Research Article Theme: Natural Products Drug Discovery in Cancer Prevention

Abstract

3,3′-diindolylmethane (DIM) is currently being investigated in many clinical trials including prostate, breast, and cervical cancers and has been shown to possess anticancer effects in several in vivo and in vitro models. Previously, DIM has been reported to possess cancer chemopreventive effects in prostate carcinogenesis in TRAMP mice; however, the in vivo mechanism is unclear. The present study aims to investigate the in vitro and in vivo epigenetics modulation of DIM in TRAMP-C1 cells and in TRAMP mouse model. In vitro study utilizing TRAMP-C1 cells showed that DIM suppressed DNMT expression and reversed CpG methylation status of Nrf2 resulting in enhanced expression of Nrf2 and Nrf2-target gene NQO1. In vivo study, TRAMP mice fed with DIM-supplemented diet showed much lower incidence of tumorigenesis and metastasis than the untreated control group similar to what was reported previously. DIM increased apoptosis, decreased cell proliferation and enhanced Nrf2 and Nrf2-target gene NQO1 expression in prostate tissues. Importantly, immunohistochemical analysis showed that DIM reduced the global CpG 5-methylcytosine methylation. Focusing on one of the early cancer chemopreventive target gene Nrf2, bisulfite genomic sequencing showed that DIM decreased the methylation status of the first five CpGs of the Nrf2 promoter region, corroborating with the results of in vitro TRAMP-C1 cells. In summary, our current study shows that DIM is a potent cancer chemopreventive agent for prostate cancer and epigenetic modifications of the CpG including Nrf2 could be a potential mechanism by which DIM exerts its chemopreventive effects.

KEY WORDS

3,3′-diindolylmethane (DIM) epigenetic methylation Nrf2 prostate cancer 

Notes

ACKNOWLEDGMENTS

We thank Dr. Chungxiou Wang as a histopathologist for her assistance in histology evaluation. We also thank Dr. Barbara Foster, Rowell Park Cancer Institute, Buffalo, NY, who generously provided the TRAMP-C1 cells. We thank all members in Dr. Kong’s group for their generous help in discussion and preparation of this manuscript.

Conflict of Interest Statement

None declared

Funding

This work was supported by Institutional Funds to Dr. Ah-Ng Tony Kong.

Supplementary material

12248_2013_9493_Fig7_ESM.jpg (44 kb)
Supplementary Fig. 1

Immunohistochemical analysis of the effects of cell proliferation, PCNA. Representative photomicrographs (×40 magnification) of PCNA-stained (dark brown color) TRAMP prostate tissue section and percentage levels of cell proliferation. The scale bar stands for 500 μm. p < 0.05, significantly different from the control and was based on Mann–Whitney U test. (JPEG 43 kb)

12248_2013_9493_MOESM1_ESM.tif (44.7 mb)
High-resolution image (TIFF 45,813 kb)
12248_2013_9493_Fig8_ESM.jpg (46 kb)
Supplementary Fig. 2

Immunohistochemical analysis of the effects of apoptosis, TUNEL. Representative photomicrographs (×40 magnification) of TUNEL stained (dark brown color) TRAMP prostate tissue section and percentage levels of apoptosis. The scale bar stands for 500 μm. *p < 0.05, significantly different from the control by Mann–Whitney U test. Number sign indicates significantly different between D-G1 and D-G2 (p = 0.043). (JPEG 46 kb)

12248_2013_9493_MOESM2_ESM.tif (44.6 mb)
High-resolution image (TIFF 45,718 kb)
12248_2013_9493_MOESM3_ESM.doc (32 kb)
Supplementary Table I Murine primers for qPCR (DOC 32 kb)
12248_2013_9493_MOESM4_ESM.doc (28 kb)
Supplementary Table II Confirmation of genotype of the TRAMP mice (DOC 28 kb)
12248_2013_9493_MOESM5_ESM.doc (28 kb)
Supplementary Table III DIM inhibit palpable tumor and metastasis in TRAMP males. aNumbers represent the presence of palpable tumor showed at the end of the experiment at 24 weeks of age. Fisher’s exact test was used to compare the incidence of palpable tumor between the control and the DIM-treated mice killed at 24 weeks of age. *p values < 0.05 were considered as significant. bNumbers represent the presence of lymph nodes metastasis showed at the end of experiment when the mice were killed. Fisher’s exact test was used to compare the incidence of lymph node metastasis between the control and the DIM treated mice sacrificed at 24 weeks of age. #p values < 0.05 were considered as significant. (DOC 27 kb)
12248_2013_9493_MOESM6_ESM.pdf (13 kb)
Supplementary Table IV TRAMP mice body weights, wet GU weights, and normalized wet GU weights by body weights measured weekly. (PDF 12 kb)

REFERENCES

  1. 1.
    Sharma S, Kelly TK, Jones PA. Epigenetics in cancer. Carcinogenesis. 2010;31(1):27–36.PubMedCrossRefGoogle Scholar
  2. 2.
    Huang J, Plass C, Gerhauser C. Cancer chemoprevention by targeting the epigenome. Curr Drug Targets. 2011;12(13):1925–56.PubMedCrossRefGoogle Scholar
  3. 3.
    Nelson WG, De Marzo AM, Yegnasubramanian S. Epigenetic alterations in human prostate cancers. Endocrinology. 2009;150(9):3991–4002.PubMedCrossRefGoogle Scholar
  4. 4.
    Pathak SK, Sharma RA, Steward WP, Mellon JK, Griffiths TR, Gescher AJ. Oxidative stress and cyclooxygenase activity in prostate carcinogenesis: targets for chemopreventive strategies. Eur J Cancer. 2005;41(1):61–70.PubMedCrossRefGoogle Scholar
  5. 5.
    Barve A, Khor TO, Nair S, Reuhl K, Suh N, Reddy B, et al. Gamma-tocopherol-enriched mixed tocopherol diet inhibits prostate carcinogenesis in TRAMP mice. Int J Cancer. 2009;124(7):1693–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Frohlich DA, McCabe MT, Arnold RS, Day ML. The role of Nrf2 in increased reactive oxygen species and DNA damage in prostate tumorigenesis. Oncogene. 2008;27(31):4353–62.PubMedCrossRefGoogle Scholar
  7. 7.
    Hayes JD, McMahon M, Chowdhry S, Dinkova-Kostova AT. Cancer chemoprevention mechanisms mediated through the Keap1-Nrf2 pathway. Antioxid Redox Signal. 2010;13(11):1713–48.PubMedCrossRefGoogle Scholar
  8. 8.
    Hu R, Saw CL, Yu R, Kong AN. Regulation of NF-E2-related factor 2 signaling for cancer chemoprevention: antioxidant coupled with antiinflammatory. Antioxid Redox Signal. 2010;13(11):1679–98.PubMedCrossRefGoogle Scholar
  9. 9.
    Barve A, Khor TO, Hao X, Keum YS, Yang CS, Reddy B, et al. Murine prostate cancer inhibition by dietary phytochemicals–curcumin and phenyethylisothiocyanate. Pharm Res. 2008;25(9):2181–9.PubMedCrossRefGoogle Scholar
  10. 10.
    Wu TY, Saw CL, Khor TO, Pung D, Boyanapalli SS, Kong AN. In vivo pharmacodynamics of indole-3-carbinol in the inhibition of prostate cancer in transgenic adenocarcinoma of mouse prostate (TRAMP) mice: involvement of Nrf2 and cell cycle/apoptosis signaling pathways. Mol Carcinog. 2012;51(10):761–70.Google Scholar
  11. 11.
    Yu S, Khor TO, Cheung KL, Li W, Wu TY, Huang Y, et al. Nrf2 expression is regulated by epigenetic mechanisms in prostate cancer of TRAMP mice. PLoS One. 2010;5(1):e8579.PubMedCrossRefGoogle Scholar
  12. 12.
    Huang Y, Khor TO, Shu L, Saw CL, Wu TY, Suh N, et al. A gamma-tocopherol-rich mixture of tocopherols maintains Nrf2 expression in prostate tumors of TRAMP mice via epigenetic inhibition of CpG methylation. J Nutr. 2012;142(5):818–23.PubMedCrossRefGoogle Scholar
  13. 13.
    Li Y, Tollefsbol TO. Impact on DNA methylation in cancer prevention and therapy by bioactive dietary components. Curr Med Chem. 2010;17(20):2141–51. Epub 2010/04/29.PubMedCrossRefGoogle Scholar
  14. 14.
    Khor TO, Huang Y, Wu TY, Shu L, Lee J, Kong AN. Pharmacodynamics of curcumin as DNA hypomethylation agent in restoring the expression of Nrf2 via promoter CpGs demethylation. Biochem Pharmacol. 2011;82(9):1073–8. Epub 2011/07/27.PubMedCrossRefGoogle Scholar
  15. 15.
    Shu L, Khor TO, Lee JH, Boyanapalli SS, Huang Y, Wu TY, et al. Epigenetic CpG Demethylation of the promoter and reactivation of the expression of Neurog1 by curcumin in prostate LNCaP cells. AAPS J. 2011;13(4):606–14.PubMedCrossRefGoogle Scholar
  16. 16.
    Weng JR, Tsai CH, Kulp SK, Chen CS. Indole-3-carbinol as a chemopreventive and anti-cancer agent. Cancer Lett. 2008;262(2):153–63.PubMedCrossRefGoogle Scholar
  17. 17.
    Sarkar FH, Li Y. Indole-3-carbinol and prostate cancer. J Nutr. 2004;134(12 Suppl):3493S–8S.PubMedGoogle Scholar
  18. 18.
    Banerjee S, Kong D, Wang Z, Bao B, Hillman GG, Sarkar FH. Attenuation of multi-targeted proliferation-linked signaling by 3,3′-diindolylmethane (DIM): from bench to clinic. Mutat Res. 2011;728(1–2):47–66.PubMedGoogle Scholar
  19. 19.
    Beaver LM, Yu TW, Sokolowski EI, Williams DE, Dashwood RH, Ho E. 3,3′-diindolylmethane, but not indole-3-carbinol, inhibits histone deacetylase activity in prostate cancer cells. Toxicol Appl Pharmacol. 2012;263(3):345–51.PubMedCrossRefGoogle Scholar
  20. 20.
    Wakabayashi N, Slocum SL, Skoko JJ, Shin S, Kensler TW. When NRF2 talks, who’s listening? Antioxid Redox Signal. 2010;13(11):1649–63.PubMedCrossRefGoogle Scholar
  21. 21.
    Foster BA, Gingrich JR, Kwon ED, Madias C, Greenberg NM. Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Cancer Res. 1997;57(16):3325–30.PubMedGoogle Scholar
  22. 22.
    Barve A, Khor TO, Nair S, Lin W, Yu S, Jain MR, et al. Pharmacogenomic profile of soy isoflavone concentrate in the prostate of Nrf2 deficient and wild-type mice. J Pharm Sci. 2008;97(10):4528–45.PubMedCrossRefGoogle Scholar
  23. 23.
    Thu KL, Pikor LA, Kennett JY, Alvarez CE, Lam WL. Methylation analysis by DNA immunoprecipitation. J Cell Physiol. 2010;222(3):522–31.PubMedGoogle Scholar
  24. 24.
    Weber M, Davies JJ, Wittig D, Oakeley EJ, Haase M, Lam WL, et al. Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells. Nat Genet. 2005;37(8):853–62.PubMedCrossRefGoogle Scholar
  25. 25.
    Cheung HH, Lee TL, Davis AJ, Taft DH, Rennert OM, Chan WY. Genome-wide DNA methylation profiling reveals novel epigenetically regulated genes and non-coding RNAs in human testicular cancer. Br J Cancer. 2010;102(2):419–27.PubMedCrossRefGoogle Scholar
  26. 26.
    Anderton MJ, Manson MM, Verschoyle R, Gescher A, Steward WP, Williams ML, et al. Physiological modeling of formulated and crystalline 3,3′-diindolylmethane pharmacokinetics following oral administration in mice. Drug Metab Dispos. 2004;32(6):632–8.PubMedCrossRefGoogle Scholar
  27. 27.
    Reed GA, Sunega JM, Sullivan DK, Gray JC, Mayo MS, Crowell JA, et al. Single-dose pharmacokinetics and tolerability of absorption-enhanced 3,3′-diindolylmethane in healthy subjects. Cancer Epidemiol Biomarkers Prev. 2008;17(10):2619–24.PubMedCrossRefGoogle Scholar
  28. 28.
    Khor TO, Yu S, Barve A, Hao X, Hong JL, Lin W, et al. Dietary feeding of dibenzoylmethane inhibits prostate cancer in transgenic adenocarcinoma of the mouse prostate model. Cancer Res. 2009;69(17):7096–102.PubMedCrossRefGoogle Scholar
  29. 29.
    Park JH, Walls JE, Galvez JJ, Kim M, Abate-Shen C, Shen MM, et al. Prostatic intraepithelial neoplasia in genetically engineered mice. Am J Pathol. 2002;161(2):727–35.PubMedCrossRefGoogle Scholar
  30. 30.
    Saw CL, Olivo M, Chin WW, Soo KC, Heng PW. Transport of hypericin across chick chorioallantoic membrane and photodynamic therapy vasculature assessment. Biol Pharm Bull. 2005;28(6):1054–60.PubMedCrossRefGoogle Scholar
  31. 31.
    Chen ZX, Riggs AD. DNA methylation and demethylation in mammals. J Biol Chem. 2011;286(21):18347–53.PubMedCrossRefGoogle Scholar
  32. 32.
    Barve A, Khor TO, Reuhl K, Reddy B, Newmark H, Kong AN. Mixed tocotrienols inhibit prostate carcinogenesis in TRAMP mice. Nutr Cancer. 2010;62(6):789–94.PubMedCrossRefGoogle Scholar
  33. 33.
    Taberlay PC, Jones PA. DNA methylation and cancer. Prog Drug Res. 2011;67:1–23.PubMedGoogle Scholar
  34. 34.
    Kim EJ, Shin M, Park H, Hong JE, Shin HK, Kim J, et al. Oral administration of 3,3′-diindolylmethane inhibits lung metastasis of 4T1 murine mammary carcinoma cells in BALB/c mice. J Nutr. 2009;139(12):2373–9.PubMedCrossRefGoogle Scholar
  35. 35.
    Cho HJ, Park SY, Kim EJ, Kim JK, Park JH. 3,3′-diindolylmethane inhibits prostate cancer development in the transgenic adenocarcinoma mouse prostate model. Mol Carcinog. 2011;50(2):100–12.PubMedCrossRefGoogle Scholar
  36. 36.
    Fan S, Meng Q, Saha T, Sarkar FH, Rosen EM. Low concentrations of diindolylmethane, a metabolite of indole-3-carbinol, protect against oxidative stress in a BRCA1-dependent manner. Cancer Res. 2009;69(15):6083–91.PubMedCrossRefGoogle Scholar
  37. 37.
    Kim YH, Kwon HS, Kim DH, Shin EK, Kang YH, Park JH, et al. 3,3′-diindolylmethane attenuates colonic inflammation and tumorigenesis in mice. Inflamm Bowel Dis. 2009;15(8):1164–73.PubMedCrossRefGoogle Scholar
  38. 38.
    Chinnakannu K, Chen D, Li Y, Wang Z, Dou QP, Reddy GP, et al. Cell cycle-dependent effects of 3,3′-diindolylmethane on proliferation and apoptosis of prostate cancer cells. J Cell Physiol. 2009;219(1):94–9.PubMedCrossRefGoogle Scholar
  39. 39.
    Fang M, Chen D, Yang CS. Dietary polyphenols may affect DNA methylation. J Nutr. 2007;137(1 Suppl):223S–8S.PubMedGoogle Scholar
  40. 40.
    Degner SC, Papoutsis AJ, Selmin O, Romagnolo DF. Targeting of aryl hydrocarbon receptor-mediated activation of cyclooxygenase-2 expression by the indole-3-carbinol metabolite 3,3′-diindolylmethane in breast cancer cells. J Nutr. 2009;139(1):26–32.PubMedGoogle Scholar
  41. 41.
    Li Y, Li X, Guo B. Chemopreventive agent 3,3′-diindolylmethane selectively induces proteasomal degradation of class I histone deacetylases. Cancer Res. 2010;70(2):646–54.PubMedCrossRefGoogle Scholar
  42. 42.
    Saw CL, Cintron M, Wu TY, Guo Y, Huang Y, Jeong WS, et al. Pharmacodynamics of dietary phytochemical indoles I3C and DIM: induction of Nrf2-mediated phase II drug metabolizing and antioxidant genes and synergism with isothiocyanates. Biopharm Drug Dispos. 2011;32(5):289–300.PubMedCrossRefGoogle Scholar
  43. 43.
    Kho MR, Baker DJ, Laayoun A, Smith SS. Stalling of human DNA (cytosine-5) methyltransferase at single-strand conformers from a site of dynamic mutation. J Mol Biol. 1998;275(1):67–79.PubMedCrossRefGoogle Scholar
  44. 44.
    Smith SS, Kaplan BE, Sowers LC, Newman EM. Mechanism of human methyl-directed DNA methyltransferase and the fidelity of cytosine methylation. Proc Natl Acad Sci U S A. 1992;89(10):4744–8.PubMedCrossRefGoogle Scholar
  45. 45.
    Jair KW, Bachman KE, Suzuki H, Ting AH, Rhee I, Yen RW, et al. De novo CpG island methylation in human cancer cells. Cancer Res. 2006;66(2):682–92.PubMedCrossRefGoogle Scholar
  46. 46.
    Shukla V, Coumoul X, Lahusen T, Wang RH, Xu X, Vassilopoulos A, et al. BRCA1 affects global DNA methylation through regulation of DNMT1. Cell Res. 2010;20(11):1201–15.PubMedCrossRefGoogle Scholar
  47. 47.
    Gingrich JR, Barrios RJ, Morton RA, Boyce BF, DeMayo FJ, Finegold MJ, et al. Metastatic prostate cancer in a transgenic mouse. Cancer Res. 1996;56(18):4096–102.PubMedGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2013

Authors and Affiliations

  • Tien-Yuan Wu
    • 1
  • Tin Oo Khor
    • 1
  • Zheng-Yuan Su
    • 1
  • Constance Lay-Lay Saw
    • 1
  • Limin Shu
    • 1
  • Ka-Lung Cheung
    • 1
  • Ying Huang
    • 1
  • Siwang Yu
    • 2
  • Ah-Ng Tony Kong
    • 1
    Email author
  1. 1.Center for Cancer Prevention Research, Department of Pharmaceutics, Ernest Mario School of PharmacyRutgers, The State University of New JerseyPiscatawayUSA
  2. 2.Department of Chemical Biology, School of Pharmaceutical SciencesPeking University Health Science CenterBeijingChina

Personalised recommendations